1-Propyl-8-[6-(3-trifluoromethyl-benzylamino)-pyridin-3-yl]-1,7-dihydro-purin-6-one | 1243706-68-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Propyl-8-[6-(3-trifluoromethyl-benzylamino)-pyridin-3-yl]-1,7-dihydro-purin-6-one
• 英文别名: 1-propyl-8-[6-[[3-(trifluoromethyl)phenyl]methylamino]pyridin-3-yl]-7H-purin-6-one
• CAS: 1243706-68-4
• 化学式: C₂₁H₁₉F₃N₆O
• 分子量: 428.417
• InChiKey: ARQFJAYKXLLFNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  86.3
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  5,6-二氨基-3-丙基嘧啶-2,4(1h,3h)-二酮 在 palladium on activated charcoal 四磷十氧化物 、 甲酸铵 、 氯化铵 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氯氧磷 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 89.0h， 生成 1-Propyl-8-[6-(3-trifluoromethyl-benzylamino)-pyridin-3-yl]-1,7-dihydro-purin-6-one
  参考文献：
  名称：

  Substituted Fused Pyrimidine Compounds

  摘要：

  本发明公开了式(I)的取代融合嘧啶化合物，它们的互变异构体、多晶形态、立体异构体、溶剂合物、药学上可接受的盐或含有它们的药物组合物，以及治疗由腺苷受体(AR)活性介导的疾病和病况的方法。本发明的化合物在治疗、预防或抑制可能通过腺苷受体拮抗而得到改善的疾病和疾病中具有用处，如哮喘、慢性阻塞性肺疾病、血管生成、肺纤维化、肺气肿、过敏性疾病、炎症、再灌注损伤、心肌缺血、动脉粥样硬化、高血压、充血性心力衰竭、视网膜病变、糖尿病、肥胖、炎症性胃肠道疾病和/或自身免疫性疾病。

  公开号：

  US20120115864A1

文献信息

• Substituted fused pyrimidine compounds
  申请人：Palle Venkata

  公开号：US08859566B2

  公开（公告）日：2014-10-14

  The present invention discloses substituted fused pyrimidine compounds of formula (I), their tautomers, polymorphs, stereoisomers, solvates, pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor, such as asthma, chronic obstructive pulmonary disorder, angiogenesis, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, congestive heart failure, retinopathy, diabetes mellitus, obesity, inflammatory gastrointestinal tract disorders, and/or autoimmune diseases.

  本发明公开了公式（I）的取代融合嘧啶化合物，它们的互变异构体、多晶形态、立体异构体、溶剂化物、药学上可接受的盐或包含它们的制药组合物以及治疗由腺苷受体（AR）活性介导的疾病和病症的方法。本发明的化合物在治疗、预防或抑制疾病和疾病方面是有用的，这些疾病和疾病可能易于通过腺苷受体拮抗作用而得到改善，如哮喘、慢性阻塞性肺疾病、血管生成、肺纤维化、肺气肿、过敏性疾病、炎症、再灌注损伤、心肌缺血、动脉粥样硬化、高血压、充血性心力衰竭、视网膜病变、糖尿病、肥胖症、炎症性胃肠道疾病和/或自身免疫性疾病。
• [EN] SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS<br/>[FR] COMPOSÉS DE PYRIMIDINE FUSIONNÉE SUBSTITUÉE
  申请人：ADVINUS THERAPEUTICS PRIVATE LTD

  公开号：WO2010103547A3

  公开（公告）日：2010-12-02
• SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS
  申请人：Advinus Therapeutics Private Limited

  公开号：EP2405917A2

  公开（公告）日：2012-01-18
• PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER
  申请人：IMPETIS BIOSCIENCES LTD.

  公开号：US20200316077A1

  公开（公告）日：2020-10-08

  The present disclosure discloses a pharmaceutical composition comprising compound of Formula I, Formula II, Formula III, Formula IV, and their pharmaceutically acceptable salts, analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, metabolites, and prodrugs thereof, for the manufacture of a medicament for the treatment of a condition or disorder ameliorated by inhibition of the A 2A /A 2B receptor. It further discloses the use of the pharmaceutical composition of the present disclosure, for the preparation of a medicament for the treatment of a condition or disorder selected from prostate cancer, rectal cancer, renal cancer, ovarian cancer, endometrial cancer, thyroid cancer, pancreatic cancer, breast cancer, colon cancer, bladder cancer, brain cancer, glial cancer, melanoma cancer, pineal gland cancer, or lung cancer.
• US8859566B2
  申请人：——

  公开号：US8859566B2

  公开（公告）日：2014-10-14